Congress Materials - Psych Congress 2025
2025 Psych Congress | Sep 17-21 | San Diego, CA
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Cardiometabolic Effects of Pharmacologic Treatments for Major Depressive Disorder: A Systematic Review and Network Meta-Analysis of Antidepressants and Antipsychotics
Ruth B. Grigolon, Nilanjana Dwibedi, M. Janelle Cambron-Mellott, Zhiheng Zhang
Characteristics and Clinical Outcomes of Patients with Treatment-Resistant Depression Completing Esketamine Intranasal Spray Induction Phase in the Veterans Health Administration
Jeremy Smith, Caroline Korves, Nazneen F Shaikh, Yuxian Du, Brahim K Bookhart, Dejan Milentijevic, Aimee M Near, Nabin Neupane, Jurandir J Dalle Lucca, Xiaohui Zhao
Comparative Analysis of Relapse Rate with Paliperidone Palmitate 6-Month in Schizophrenia: Randomized Controlled Study versus Matched Real-World Data
Jordy Mehawej, Ibrahim Turkoz, Mehmet Daskiran, Lucy Shao, Camilo Obando, James Simples Jr., Karen L. Johnston, R. Karl Knight, Josh Hamilton, Christoph U. Correll
Comparison of Real-world Response and Remission Among Patients with Treatment-Resistant Depression Treated with Esketamine Nasal Spray or Antipsychotic Augmentation
Kristin Clemens, Maryia Zhdanava, Yuxian Du, Arthur Voegel, Anabelle Tardif-Samson, Fengyi Jiang, Dominic Pilon, Kruti Joshi
Double-Blind and Open-Label Extension Results From a Phase 3 Trial of Seltorexant, Adjunctive to Antidepressants, in Adults With Major Depressive Disorder With Insomnia Symptoms
Gahan Pandina, Michael E. Thase, Andrew D. Krystal, Ewa Wajs, Joseph M. Trombello, Ryan Kelly, Yun Zhang, Haiyan Xu, John Thipphawong, Sandra Ruschel, Yanina Flossbach, Carla M. Canuso, Thomas Laughren, Wayne C. Drevets
Effect of Esketamine Nasal Spray Monotherapy on Emotional Blunting in Adult Patients With Treatment-Resistant Depression: A Post Hoc Analysis
Dong-Jing Fu, Ibrahim Turkoz, Patricia Cabrera, Susan Lakey, Ami Patel, Oliver Lopena, Lisa Lim, Anita H. Clayton
Efficacy and Safety of Esketamine Nasal Spray as Monotherapy in Adult Patients With Treatment-Resistant Depression for up to 4 Months of Treatment: A Post Hoc Analysis
Andrew J Cutler, Dong-Jing Fu, Ibrahim Turkoz, Mai Himedan, Oliver Lopena, Lisa Lim, John S Verbanac
Efficacy of Lumateperone 42 mg in the Treatment of Major Depressive Disorder: A Pooled Analysis of Phase 3 Randomized Controlled Trials
Willie R. Earley, Suresh Durgam, Susan G. Kozauer, Changzheng Chen, Dennis Sholler, Rakesh Jain
Long-Term Adjunctive Lumateperone Treatment in Major Depressive Disorder: Results From a Six-Month Open-Label Extension Study
Willie R. Earley, Suresh Durgam, Susan G. Kozauer, Changzheng Chen, Dri Wang, Andrew J. Cutler
Long-Term Safety and Efficacy of Esketamine Nasal Spray Maintenance Dosing After a Lapse in Treatment: A Post Hoc Analysis of the SUSTAIN-3 Study
John Zajecka, Dong-Jing Fu, Ibrahim Turkoz, Oliver Lopena, Lisa Lim, Brianne Brown, Muhammad Ahmed, Patricia Cabrera, Manish Patel
Long-Term Safety and Efficacy of Esketamine Nasal Spray as Monotherapy: A Post Hoc Analysis of the SUSTAIN-3 Study
John Zajecka, Dong-Jing Fu, Ibrahim Turkoz, Patricia Cabrera, Oliver Lopena, Lisa Lim, Megan Kunka Fritz, Muhammad Ahmed
Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder and Anxious Distress
Suresh Durgam, Willie R. Earley, Susan G. Kozauer, Changzheng Chen, Betsy Yuan, Gary S. Sachs
Lumateperone for the Prevention of Relapse in Patients with Schizophrenia: Results From a Double-Blind, Placebo-Controlled, Randomized Withdrawal, Phase 3 Trial
Suresh Durgam, Willie R. Earley, Susan G. Kozauer, Jason Huo, Hassan Lakkis, Giridhar Maddirevula, Niko Wagner, Christoph U. Correll
Lumateperone Treatment for Major Depressive Episodes with Mixed Features in Major Depressive Disorder and Bipolar I or Bipolar II Disorder: A Post Hoc Analysis of Anhedonia
Suresh Durgam, Susan G. Kozauer, Willie R. Earley, Jason Huo, Tobie Escher, Lakshmi N. Yatham
Major Depressive Disorder Patient Voice: AI-Assisted Insights from Inspire’s Online Health Community Platform
Josh Feldman, Brian Chen, Valmeek Kudesia, Tiina Drissen, Hrishikesh Hale
Montgomery-Åsberg Depression Rating Scale Anhedonia Factor Score Following Esketamine Nasal Spray Monotherapy in Adult Patients With Treatment-Resistant Depression: A Post Hoc Analysis
Craig Chepke, Mai Himedan, Dong-Jing Fu, Oliver Lopena, Allen Wu, Ibrahim Turkoz, Lilianna Ly, Lisa Lim, Matthew Macaluso
Patient and Clinician Satisfaction and Quality of Life of Patients with Schizophrenia Using Paliperidone Palmitate 1-Month and 3-Month Long Acting Injectables in Rwanda
Jordy Mehawej, José Antunes, Ibrahim Turkoz, Rutakayile Bizoza, Larry Alphs, Leslie Killion, R. Karl Knight
Response and Remission on Esketamine Nasal Spray in Patients With Treatment-Resistant Depression Overall and Among TMS-Naive Subgroup
Tobias Marton, Kruti Joshi, Maryia Zhdanava, Aditi Shah, Dominic Pilon, Bronwyn Moore, Fengyi Jiang, Jennifer Guo
Safety and Tolerability of Lumateperone 42 mg for the Adjunctive Treatment of Major Depressive Disorder: A Pooled Analysis of 2 Randomized Placebo-Controlled Trials
Willie R. Earley, Suresh Durgam, Susan G. Kozauer, Changzheng Chen, Hassan Lakkis, Alvin B. Oung, Christoph U. Correll
Seltorexant Versus Quetiapine Extended Release as Adjunctive Treatment in Major Depressive Disorder With Insomnia Symptoms: Phase 3 Trial
Yanina Flossbach, Sofie Mesens, Gahan Pandina, Ryan Kelly, Yun Zhang, Haiyan Xu, Lu Xia, Carla M. Canuso, Wayne C. Drevets
Treatment Effects of Paliperidone Palmitate 6-Month Formulation on Negative Symptoms in Patients With Schizophrenia: Post-Hoc Analysis Over 3 Years
Jordy Mehawej, José Antunes, Camilo Obando, Ibrahim Turkoz, Liping Sun, Leslie Killion, R. Karl Knight
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
